Pneumonia halted treatment while her breast cancer was responding

After she was admitted to the hospital, Emma kept thinking about the cancer tablets she was no longer taking.

A few months earlier, scans had shown a partial response. She and her family had begun to settle into a routine of medication, injections and follow-up appointments. Now she had a fever, a cough and inflammation in her lungs, and cancer treatment had been suspended.

She understood that the doctors needed to deal with the new illness. She still worried about what might happen to the cancer while a treatment that had been working was put on hold.

Within days, breathing would become the more urgent concern.

Emma was 52 when she was diagnosed with breast cancer in February 2023 at Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine. Biopsies of breast and lung lesions confirmed that the cancer had spread to her lungs.

At first, she struggled to understand why a disease found in her breast was also appearing on a chest scan. As the doctor explained metastasis, she began to grasp why treatment had to address cancer beyond the breast.

Before she became ill, Emma worked in a shop. She spent much of the day on her feet, talking to customers and answering the same questions. On a busy day she might talk for hours. When she took a break, she sometimes wanted only to sit down and be quiet.

After the diagnosis, explaining her health to people became tiring. When acquaintances asked, she usually said she was having treatment. She did not want to tell the whole story each time.

She still called colleagues to ask whether the shop was busy or how a problem had been sorted out. It helped to have a conversation about something she knew that had nothing to do with being ill.

Her cancer was hormone receptor-positive and HER2-negative. The doctors prescribed abemaciclib with letrozole and goserelin. Abemaciclib interferes with processes involved in cell division; the other two drugs work through hormone therapy to reduce the stimulation the cancer receives from hormones.

It took her a while to learn the names. She was more concerned with taking the medication on time, keeping appointments and knowing what to do if she felt unwell.

Several months into treatment, scans showed a partial response.

The lung lesions had frightened her. Knowing the treatment was helping allowed her to think a little further ahead. There were still tablets and tests, but a hospital visit no longer seemed certain to bring bad news.

In August, fever, fatigue and a cough brought her back into hospital. With cancer already in her lungs, her first fear was that the improvement had not lasted.

The chest CT showed a few remaining metastatic lesions, but also widespread interstitial inflammation in both lungs. Blood tests found raised inflammatory markers and substantially reduced numbers of lymphocytes and some of their subtypes, cells involved in immune defense.

The doctors considered infection and drug-related lung injury. Her cancer history alone could not explain the new findings.

They paused her cancer treatment and initially treated her for suspected bacterial pneumonia. Emma hoped that once the fever settled she could return to her previous regimen. She was already wondering how the interruption would affect her next assessment.

After three days of antibiotics, however, she had not improved.

Her temperature reached 39.6°C. Breathing room air, her oxygen saturation fell to 71 percent.

Speaking took effort. She shortened what she wanted to say and sometimes answered her family's questions with a nod or a shake of the head. For the moment, thoughts about her next cancer treatment receded.

The team gave her high-flow oxygen through a nasal cannula and continued investigating. They performed a bronchoalveolar lavage to collect material from the lower airways. Among the tests was one that looked for genetic material from possible pathogens.

It detected Pneumocystis jirovecii, a fungus that can cause severe pneumonia in people with weakened immune defenses. Taken with her symptoms, scans, severe oxygen shortage and immune cell findings, the result supported a diagnosis of Pneumocystis pneumonia.

Emma had never heard of it. Once she was well enough to listen, she wanted to know whether the doctors had now found a cause they could treat specifically.

She had developed marked lymphopenia, a low lymphocyte count, during the abemaciclib combination treatment. That may have made her more vulnerable to an opportunistic infection. The team needed to reassess her cancer medication in light of what had happened to her immune defenses.

They started trimethoprim-sulfamethoxazole to treat the infection, together with corticosteroids and other supportive care.

Four days later, her temperature was normal.

Her cough, breathlessness and fatigue gradually eased. Inflammatory markers improved, and her lymphocyte count began to recover.

She could speak for longer without mentally cutting each answer short. When her family talked, she had enough energy to ask how things were at home. She was still tired, but breathing no longer demanded all her attention.

Emma was discharged on the fourteenth day in hospital. She continued treatment as an outpatient, including medication for the infection and a gradual reduction in steroids under her doctor's direction.

Her family checked the new instructions carefully so they would not confuse them with her previous cancer regimen.

This time, she did not press to restart the old tablets immediately. She still worried about the cancer, but had experienced how quickly another illness could make continuing treatment impossible.

About a month later, a chest CT showed partial resolution of the inflammatory changes. The persistent fever and marked respiratory symptoms from her admission had subsided. Her lungs still needed time and follow-up, but the infection was coming under control.

The conversation returned to cancer treatment.

Emma had mixed feelings about abemaciclib. The earlier combination had brought a partial response, and she remembered the relief of that scan result. But the severe infection and the drop in her immune cells could not be set aside.

She told the doctor that she wanted to keep treating the cancer and was afraid of becoming so breathless again.

About two months later, cancer treatment resumed. Abemaciclib was discontinued, and the regimen changed to fulvestrant with goserelin, continuing a hormonal approach to her breast cancer.

Previously, Emma had focused mostly on whether the tumors were getting smaller. Now she was more ready to mention a fever, a cough or a change in her energy, and to ask about blood results that did not directly measure the cancer.

At the appointment when treatment resumed, a family member was about to explain how she had been since the hospital stay. Emma indicated that she would tell the doctor herself.

She described when the fever had gone, which symptoms had improved and what still bothered her. She paused to think, then added two questions she had been meaning to ask.

This time, she could take her time and finish what she wanted to say.